Format

Send to

Choose Destination
Clin Cancer Res. 2016 May 1;22(9):2102-4. doi: 10.1158/1078-0432.CCR-16-0169. Epub 2016 Mar 8.

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.

Author information

1
Department of Pathology, Yale School of Medicine, New Haven, Connecticut. Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut. kurt.schalper@yale.edu.
2
Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut.
3
Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut.

Abstract

Blockade of the PD-1 axis has emerged as an effective anticancer immunotherapy against various tumor types. Diverse studies have identified biomarkers associated with response to these therapies. However, the clinical use of such tests is limited by their variable performance and restricted understanding of their biologic significance. Clin Cancer Res; 22(9); 2102-4. ©2016 AACRSee related article by Ock et al., p. 2261.

PMID:
26957559
PMCID:
PMC4940186
DOI:
10.1158/1078-0432.CCR-16-0169
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center